{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T22:01:07Z","timestamp":1762898467239},"reference-count":55,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2009,2,1]],"date-time":"2009-02-01T00:00:00Z","timestamp":1233446400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2009,2]]},"DOI":"10.1016\/j.vaccine.2008.12.035","type":"journal-article","created":{"date-parts":[[2009,1,14]],"date-time":"2009-01-14T09:23:41Z","timestamp":1231925021000},"page":"1154-1165","source":"Crossref","is-referenced-by-count":25,"title":["The heterogeneity of human antibody responses to vaccinia virus revealed through use of focused protein arrays"],"prefix":"10.1016","volume":"27","author":[{"given":"Jonathan S.","family":"Duke-Cohan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristin","family":"Wollenick","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth A.","family":"Witten","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael S.","family":"Seaman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lindsey R.","family":"Baden","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raphael","family":"Dolin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ellis L.","family":"Reinherz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"October 20 (15)","key":"10.1016\/j.vaccine.2008.12.035_bib1","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1001\/jama.292.15.1887","article-title":"Emerging infectious diseases: a clear and present danger to humanity","volume":"292","author":"Fauci","year":"2004","journal-title":"JAMA"},{"issue":"July 8 (6996)","key":"10.1016\/j.vaccine.2008.12.035_bib2","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1038\/nature02759","article-title":"The challenge of emerging and re-emerging infectious diseases","volume":"430","author":"Morens","year":"2004","journal-title":"Nature"},{"issue":"April (4)","key":"10.1016\/j.vaccine.2008.12.035_bib3","doi-asserted-by":"crossref","first-page":"519","DOI":"10.3201\/eid1104.041167","article-title":"Emerging infectious diseases: a 10-year perspective from the National Institute of Allergy and Infectious Diseases","volume":"11","author":"Fauci","year":"2005","journal-title":"Emerg Infect Dis"},{"issue":"March 18 (6)","key":"10.1016\/j.vaccine.2008.12.035_bib4","doi-asserted-by":"crossref","first-page":"488","DOI":"10.7326\/0003-4819-138-6-200303180-00014","article-title":"Evaluation of 21st-century risks of smallpox vaccination and policy options","volume":"138","author":"Lane","year":"2003","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.vaccine.2008.12.035_bib5","unstructured":"Rotz LD, Dotson DA, Damon IK, Becher JA. Vaccinia (smallpox) vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2001. MMWR Recomm Rep 2001 June 22;50(RR-10):1\u201325; quiz CE1-7."},{"issue":"June 9 (22)","key":"10.1016\/j.vaccine.2008.12.035_bib6","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1001\/jama.281.22.2127","article-title":"Smallpox as a biological weapon: medical and public health management","volume":"281","author":"Henderson","year":"1999","journal-title":"JAMA"},{"issue":"April 25 (17)","key":"10.1016\/j.vaccine.2008.12.035_bib7","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1056\/NEJMoa013431","article-title":"Dose-related effects of smallpox vaccine","volume":"346","author":"Frey","year":"2002","journal-title":"N Engl J Med"},{"issue":"May (2)","key":"10.1016\/j.vaccine.2008.12.035_bib8","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/0196-6553(82)90003-7","article-title":"The global eradication of smallpox","volume":"10","author":"Strassburg","year":"1982","journal-title":"Am J Infect Control"},{"key":"10.1016\/j.vaccine.2008.12.035_bib9","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/1471-2458-3-26","article-title":"Risks of serious complications and death from smallpox vaccination: a systematic review of the United States experience, 1963\u20131968","volume":"3 (August 11)","author":"Aragon","year":"2003","journal-title":"BMC Public Health"},{"key":"10.1016\/j.vaccine.2008.12.035_bib10","unstructured":"Cono J, Casey CG, Bell DM. Smallpox vaccination and adverse reactions. Guidance for clinicians. MMWR Recomm Rep 2003 February 21;52(RR-4):1\u201328."},{"issue":"March 15 (Suppl. 3)","key":"10.1016\/j.vaccine.2008.12.035_bib11","doi-asserted-by":"crossref","first-page":"S242","DOI":"10.1086\/524747","article-title":"Myocarditis, pericarditis, and dilated cardiomyopathy after smallpox vaccination among civilians in the United States, January\u2013October 2003","volume":"46","author":"Morgan","year":"2008","journal-title":"Clin Infect Dis"},{"issue":"June 15 (12)","key":"10.1016\/j.vaccine.2008.12.035_bib12","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1086\/421266","article-title":"Modified vaccinia Ankara: potential as an alternative smallpox vaccine","volume":"38","author":"McCurdy","year":"2004","journal-title":"Clin Infect Dis"},{"issue":"September (3)","key":"10.1016\/j.vaccine.2008.12.035_bib13","doi-asserted-by":"crossref","first-page":"263","DOI":"10.2174\/1568005033481123","article-title":"Vaccinia vectors as candidate vaccines: the development of modified vaccinia virus Ankara for antigen delivery","volume":"3","author":"Sutter","year":"2003","journal-title":"Curr Drug Targets Infect Disord"},{"issue":"January (2)","key":"10.1016\/j.vaccine.2008.12.035_bib14","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1128\/JVI.01706-07","article-title":"Antibody profiling by proteome microarray reveals the immunogenicity of the attenuated smallpox vaccine modified vaccinia virus Ankara is comparable to that of Dryvax","volume":"82","author":"Davies","year":"2008","journal-title":"J Virol"},{"issue":"June 11 (6)","key":"10.1016\/j.vaccine.2008.12.035_bib15","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1084\/jem.20062363","article-title":"Immunization with vaccinia virus induces polyfunctional and phenotypically distinctive CD8(+) T cell responses","volume":"204","author":"Precopio","year":"2007","journal-title":"J Exp Med"},{"issue":"February 5 (1)","key":"10.1016\/j.vaccine.2008.12.035_bib16","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.virol.2007.09.029","article-title":"Immunogenicity and protection efficacy of subunit-based smallpox vaccines using variola major antigens","volume":"371","author":"Sakhatskyy","year":"2008","journal-title":"Virology"},{"issue":"October (19)","key":"10.1016\/j.vaccine.2008.12.035_bib17","doi-asserted-by":"crossref","first-page":"10230","DOI":"10.1128\/JVI.78.19.10230-10237.2004","article-title":"Protective immunity to vaccinia virus induced by vaccination with multiple recombinant outer membrane proteins of intracellular and extracellular virions","volume":"78","author":"Fogg","year":"2004","journal-title":"J Virol"},{"issue":"April 12 (15)","key":"10.1016\/j.vaccine.2008.12.035_bib18","doi-asserted-by":"crossref","first-page":"2787","DOI":"10.1016\/j.vaccine.2006.12.037","article-title":"Adjuvant-enhanced antibody responses to recombinant proteins correlates with protection of mice and monkeys to orthopoxvirus challenges","volume":"25","author":"Fogg","year":"2007","journal-title":"Vaccine"},{"issue":"February 1 (1)","key":"10.1016\/j.vaccine.2008.12.035_bib19","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S0042-6822(02)00038-7","article-title":"Four-gene-combination DNA vaccine protects mice against a lethal vaccinia virus challenge and elicits appropriate antibody responses in nonhuman primates","volume":"306","author":"Hooper","year":"2003","journal-title":"Virology"},{"issue":"November 25 (2)","key":"10.1016\/j.vaccine.2008.12.035_bib20","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.virol.2006.07.017","article-title":"Immunogenicity and protection efficacy of monovalent and polyvalent poxvirus vaccines that include the D8 antigen","volume":"355","author":"Sakhatskyy","year":"2006","journal-title":"Virology"},{"key":"10.1016\/j.vaccine.2008.12.035_bib21","first-page":"86","article-title":"Differences between extracellular and intracellular forms of poxvirus and their implications","volume":"16","author":"Boulter","year":"1973","journal-title":"Prog Med Virol"},{"issue":"September 17 (19)","key":"10.1016\/j.vaccine.2008.12.035_bib22","doi-asserted-by":"crossref","first-page":"12415","DOI":"10.1073\/pnas.192420599","article-title":"Cloning the vaccinia virus genome as a bacterial artificial chromosome in Escherichia coli and recovery of infectious virus in mammalian cells","volume":"99","author":"Domi","year":"2002","journal-title":"Proc Natl Acad Sci USA"},{"issue":"January 26 (7)","key":"10.1016\/j.vaccine.2008.12.035_bib23","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1016\/j.vaccine.2006.10.009","article-title":"A protein-based smallpox vaccine protects mice from vaccinia and ectromelia virus challenges when given as a prime and single boost","volume":"25","author":"Xiao","year":"2007","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2008.12.035_bib24","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1186\/1471-2105-7-225","article-title":"JColorGrid: software for the visualization of biological measurements","volume":"7","author":"Joachimiak","year":"2006","journal-title":"BMC Bioinform"},{"key":"10.1016\/j.vaccine.2008.12.035_bib25","series-title":"Vaccinia virus and poxvirology: methods and protocols","article-title":"Growing poxviruses and determining virus titer","author":"Kotwal","year":"2004"},{"issue":"September (9)","key":"10.1016\/j.vaccine.2008.12.035_bib26","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1038\/nm917","article-title":"Duration of antiviral immunity after smallpox vaccination","volume":"9","author":"Hammarlund","year":"2003","journal-title":"Nat Med"},{"issue":"May (10)","key":"10.1016\/j.vaccine.2008.12.035_bib27","doi-asserted-by":"crossref","first-page":"6260","DOI":"10.1128\/JVI.79.10.6260-6271.2005","article-title":"Epitope-mapping studies define two major neutralization sites on the vaccinia virus extracellular enveloped virus glycoprotein B5R","volume":"79","author":"Aldaz-Carroll","year":"2005","journal-title":"J Virol"},{"issue":"October (10)","key":"10.1016\/j.vaccine.2008.12.035_bib28","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1111\/j.1600-0854.2005.00324.x","article-title":"Cytoplasmic organization of POXvirus DNA replication","volume":"6","author":"Schramm","year":"2005","journal-title":"Traffic"},{"issue":"October 11 (4)","key":"10.1016\/j.vaccine.2008.12.035_bib29","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.chom.2007.08.005","article-title":"Colocalization of transcription and translation within cytoplasmic poxvirus factories coordinates viral expression and subjugates host functions","volume":"2","author":"Katsafanas","year":"2007","journal-title":"Cell Host Microb"},{"issue":"December (Pt 12)","key":"10.1016\/j.vaccine.2008.12.035_bib30","doi-asserted-by":"crossref","first-page":"2915","DOI":"10.1099\/0022-1317-83-12-2915","article-title":"The formation and function of extracellular enveloped vaccinia virus","volume":"83","author":"Smith","year":"2002","journal-title":"J Gen Virol"},{"issue":"March 15 (3)","key":"10.1016\/j.vaccine.2008.12.035_bib31","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1111\/j.1432-1033.1988.tb13940.x","article-title":"tRNA-mediated labelling of proteins with biotin. A nonradioactive method for the detection of cell-free translation products","volume":"172","author":"Kurzchalia","year":"1988","journal-title":"Eur J Biochem"},{"key":"10.1016\/j.vaccine.2008.12.035_bib32","unstructured":"Promega. Transcend non-radioactive translation detection systems. Technical Bulletin TB182: Promega Corporation, 2006."},{"issue":"January 18 (3)","key":"10.1016\/j.vaccine.2008.12.035_bib33","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1073\/pnas.0408782102","article-title":"Profiling the humoral immune response to infection by using proteome microarrays: high-throughput vaccine and diagnostic antigen discovery","volume":"102","author":"Davies","year":"2005","journal-title":"Proc Natl Acad Sci USA"},{"issue":"November (11)","key":"10.1016\/j.vaccine.2008.12.035_bib34","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1038\/nm1457","article-title":"Quantification of antibody responses against multiple antigens of the two infectious forms of Vaccinia virus provides a benchmark for smallpox vaccination","volume":"12","author":"Putz","year":"2006","journal-title":"Nat Med"},{"issue":"1","key":"10.1016\/j.vaccine.2008.12.035_bib35","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1089\/vim.2005.18.138","article-title":"Polyclonal hypergammaglobulinemia and formation of hydrophobic immune complexes in porcine reproductive and respiratory syndrome virus-infected and uninfected pigs","volume":"18","author":"Plagemann","year":"2005","journal-title":"Viral Immunol"},{"issue":"April (7)","key":"10.1016\/j.vaccine.2008.12.035_bib36","doi-asserted-by":"crossref","first-page":"3751","DOI":"10.1128\/JVI.02244-07","article-title":"Redundancy and plasticity of neutralizing antibody responses are cornerstone attributes of the human immune response to the smallpox vaccine","volume":"82","author":"Benhnia","year":"2008","journal-title":"J Virol"},{"issue":"May (10)","key":"10.1016\/j.vaccine.2008.12.035_bib37","doi-asserted-by":"crossref","first-page":"1678","DOI":"10.1002\/pmic.200600926","article-title":"Proteome-wide analysis of the serological response to vaccinia and smallpox","volume":"7","author":"Davies","year":"2007","journal-title":"Proteomics"},{"issue":"December 17 (50)","key":"10.1016\/j.vaccine.2008.12.035_bib38","doi-asserted-by":"crossref","first-page":"15093","DOI":"10.1021\/bi026455d","article-title":"Engineering the protein N-glycosylation pathway in insect cells for production of biantennary, complex N-glycans","volume":"41","author":"Hollister","year":"2002","journal-title":"Biochemistry"},{"issue":"September (18)","key":"10.1016\/j.vaccine.2008.12.035_bib39","doi-asserted-by":"crossref","first-page":"11724","DOI":"10.1128\/JVI.79.18.11724-11733.2005","article-title":"Vaccinia virus H3L envelope protein is a major target of neutralizing antibodies in humans and elicits protection against lethal challenge in mice","volume":"79","author":"Davies","year":"2005","journal-title":"J Virol"},{"issue":"October 1 (7)","key":"10.1016\/j.vaccine.2008.12.035_bib40","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1086\/520936","article-title":"Antibodies to the A27 protein of vaccinia virus neutralize and protect against infection but represent a minor component of Dryvax vaccine-induced immunity","volume":"196","author":"He","year":"2007","journal-title":"J Infect Dis"},{"issue":"June (3)","key":"10.1016\/j.vaccine.2008.12.035_bib41","first-page":"216","article-title":"Protein arrays for biomarker discovery","volume":"9","author":"Reid","year":"2007","journal-title":"Curr Opin Mol Ther"},{"issue":"August (15)","key":"10.1016\/j.vaccine.2008.12.035_bib42","doi-asserted-by":"crossref","first-page":"8131","DOI":"10.1128\/JVI.00374-07","article-title":"Major neutralizing sites on vaccinia virus glycoprotein B5 are exposed differently on variola virus ortholog B6","volume":"81","author":"Aldaz-Carroll","year":"2007","journal-title":"J Virol"},{"issue":"August (Pt 8)","key":"10.1016\/j.vaccine.2008.12.035_bib43","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1099\/0022-1317-80-8-2137","article-title":"The vaccinia virus A4OR gene product is a nonstructural, type II membrane glycoprotein that is expressed at the cell surface","volume":"80","author":"Wilcock","year":"1999","journal-title":"J Gen Virol"},{"issue":"December (23)","key":"10.1016\/j.vaccine.2008.12.035_bib44","doi-asserted-by":"crossref","first-page":"11230","DOI":"10.1128\/JVI.74.23.11230-11239.2000","article-title":"The vaccinia virus soluble alpha\/beta interferon (IFN) receptor binds to the cell surface and protects cells from the antiviral effects of IFN","volume":"74","author":"Alcami","year":"2000","journal-title":"J Virol"},{"issue":"October (10)","key":"10.1016\/j.vaccine.2008.12.035_bib45","doi-asserted-by":"crossref","first-page":"8750","DOI":"10.1128\/JVI.73.10.8750-8761.1999","article-title":"Vaccinia virus envelope D8L protein binds to cell surface chondroitin sulfate and mediates the adsorption of intracellular mature virions to cells","volume":"73","author":"Hsiao","year":"1999","journal-title":"J Virol"},{"issue":"April (7)","key":"10.1016\/j.vaccine.2008.12.035_bib46","doi-asserted-by":"crossref","first-page":"3353","DOI":"10.1128\/JVI.74.7.3353-3365.2000","article-title":"Vaccinia virus envelope H3L protein binds to cell surface heparan sulfate and is important for intracellular mature virion morphogenesis and virus infection in vitro and in vivo","volume":"74","author":"Lin","year":"2000","journal-title":"J Virol"},{"issue":"July (2)","key":"10.1016\/j.vaccine.2008.12.035_bib47","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/0168-1702(95)00025-L","article-title":"The vaccinia virus J5L open reading frame encodes a polypeptide expressed late during infection and required for viral multiplication","volume":"37","author":"Zajac","year":"1995","journal-title":"Virus Res"},{"issue":"August 1 (2)","key":"10.1016\/j.vaccine.2008.12.035_bib48","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.virol.2004.05.004","article-title":"Antibodies against the extracellular enveloped virus B5R protein are mainly responsible for the EEV neutralizing capacity of vaccinia immune globulin","volume":"325","author":"Bell","year":"2004","journal-title":"Virology"},{"issue":"February 1 (1)","key":"10.1016\/j.vaccine.2008.12.035_bib49","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1006\/viro.2000.0750","article-title":"Antibody neutralization of the extracellular enveloped form of vaccinia virus","volume":"280","author":"Law","year":"2001","journal-title":"Virology"},{"issue":"April (7)","key":"10.1016\/j.vaccine.2008.12.035_bib50","doi-asserted-by":"crossref","first-page":"3517","DOI":"10.1128\/JVI.01854-07","article-title":"Vaccination of BALB\/c mice with Escherichia coli-expressed vaccinia virus proteins A27L, B5R, and D8L protects mice from lethal vaccinia virus challenge","volume":"82","author":"Berhanu","year":"2008","journal-title":"J Virol"},{"issue":"August 15 (4)","key":"10.1016\/j.vaccine.2008.12.035_bib51","doi-asserted-by":"crossref","first-page":"2552","DOI":"10.4049\/jimmunol.177.4.2552","article-title":"Subunit recombinant vaccine protects against monkeypox","volume":"177","author":"Heraud","year":"2006","journal-title":"J Immunol"},{"issue":"January 20 (2)","key":"10.1016\/j.vaccine.2008.12.035_bib52","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1006\/viro.1999.0096","article-title":"DNA vaccination with vaccinia virus L1R and A33R genes protects mice against a lethal poxvirus challenge","volume":"266","author":"Hooper","year":"2000","journal-title":"Virology"},{"issue":"May (9)","key":"10.1016\/j.vaccine.2008.12.035_bib53","doi-asserted-by":"crossref","first-page":"4433","DOI":"10.1128\/JVI.78.9.4433-4443.2004","article-title":"Smallpox DNA vaccine protects nonhuman primates against lethal monkeypox","volume":"78","author":"Hooper","year":"2004","journal-title":"J Virol"},{"issue":"September (18)","key":"10.1016\/j.vaccine.2008.12.035_bib54","doi-asserted-by":"crossref","first-page":"11873","DOI":"10.1128\/JVI.79.18.11873-11891.2005","article-title":"An attenuated LC16m8 smallpox vaccine: analysis of full-genome sequence and induction of immune protection","volume":"79","author":"Morikawa","year":"2005","journal-title":"J Virol"},{"issue":"June (11)","key":"10.1016\/j.vaccine.2008.12.035_bib55","doi-asserted-by":"crossref","first-page":"5179","DOI":"10.1128\/JVI.02642-05","article-title":"LC16m8, a highly attenuated vaccinia virus vaccine lacking expression of the membrane protein B5R, protects monkeys from monkeypox","volume":"80","author":"Saijo","year":"2006","journal-title":"J Virol"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X0801760X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X0801760X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,5,14]],"date-time":"2020-05-14T16:28:23Z","timestamp":1589473703000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X0801760X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,2]]},"references-count":55,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2009,2]]}},"alternative-id":["S0264410X0801760X"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2008.12.035","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2009,2]]}}}